Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 8.54 USD -0.12% Market Closed
Market Cap: 801.1m USD

EV/OCF
Enterprise Value to OCF

-8.7
Current
1.1
Median
5.7
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-8.7
=
Enterprise Value
655.8m USD
/
Operating Cash Flow
-75m USD
Market Cap EV/OCF
US
Chimerix Inc
NASDAQ:CMRX
787.5m USD -8.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -212 089.8
US
Abbvie Inc
NYSE:ABBV
336.1B USD 24.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -14 474
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 17.2
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 15.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD -116.9
US
Epizyme Inc
F:EPE
94.1B EUR -530.8
AU
CSL Ltd
ASX:CSL
129.7B AUD 31.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 14
US
Seagen Inc
F:SGT
39.3B EUR -83.3
 
US
Chimerix Inc
NASDAQ:CMRX
Average EV/OCF: 20.4
Negative Multiple: -8.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -212 089.8
US
Abbvie Inc
NYSE:ABBV
24.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -14 474
US
Amgen Inc
NASDAQ:AMGN
17.2
US
Gilead Sciences Inc
NASDAQ:GILD
15.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.8
AU
CSL Ltd
ASX:CSL
31.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
US
S
Seagen Inc
F:SGT
Negative Multiple: -83.3

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Summary
CMRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CMRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CMRX stock valuation using valuation multiples.
Wall Street Estimates
CMRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CMRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.